Theralase Technologies Inc
XTSX:TLT

Watchlist Manager
Theralase Technologies Inc Logo
Theralase Technologies Inc
XTSX:TLT
Watchlist
Price: 0.3 CAD 3.45% Market Closed
Market Cap: 72.8m CAD
Have any thoughts about
Theralase Technologies Inc?
Write Note

Intrinsic Value

The intrinsic value of one TLT stock under the Base Case scenario is 0.96 CAD. Compared to the current market price of 0.3 CAD, Theralase Technologies Inc is Undervalued by 69%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TLT Intrinsic Value
0.96 CAD
Undervaluation 69%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Theralase Technologies Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TLT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TLT?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Theralase Technologies Inc

Provide an overview of the primary business activities
of Theralase Technologies Inc.

What unique competitive advantages
does Theralase Technologies Inc hold over its rivals?

What risks and challenges
does Theralase Technologies Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Theralase Technologies Inc.

Provide P/S
for Theralase Technologies Inc.

Provide P/E
for Theralase Technologies Inc.

Provide P/OCF
for Theralase Technologies Inc.

Provide P/FCFE
for Theralase Technologies Inc.

Provide P/B
for Theralase Technologies Inc.

Provide EV/S
for Theralase Technologies Inc.

Provide EV/GP
for Theralase Technologies Inc.

Provide EV/EBITDA
for Theralase Technologies Inc.

Provide EV/EBIT
for Theralase Technologies Inc.

Provide EV/OCF
for Theralase Technologies Inc.

Provide EV/FCFF
for Theralase Technologies Inc.

Provide EV/IC
for Theralase Technologies Inc.

Show me price targets
for Theralase Technologies Inc made by professional analysts.

What are the Revenue projections
for Theralase Technologies Inc?

How accurate were the past Revenue estimates
for Theralase Technologies Inc?

What are the Net Income projections
for Theralase Technologies Inc?

How accurate were the past Net Income estimates
for Theralase Technologies Inc?

What are the EPS projections
for Theralase Technologies Inc?

How accurate were the past EPS estimates
for Theralase Technologies Inc?

What are the EBIT projections
for Theralase Technologies Inc?

How accurate were the past EBIT estimates
for Theralase Technologies Inc?

Compare the revenue forecasts
for Theralase Technologies Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Theralase Technologies Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Theralase Technologies Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Theralase Technologies Inc compared to its peers.

Compare the P/E ratios
of Theralase Technologies Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Theralase Technologies Inc with its peers.

Analyze the financial leverage
of Theralase Technologies Inc compared to its main competitors.

Show all profitability ratios
for Theralase Technologies Inc.

Provide ROE
for Theralase Technologies Inc.

Provide ROA
for Theralase Technologies Inc.

Provide ROIC
for Theralase Technologies Inc.

Provide ROCE
for Theralase Technologies Inc.

Provide Gross Margin
for Theralase Technologies Inc.

Provide Operating Margin
for Theralase Technologies Inc.

Provide Net Margin
for Theralase Technologies Inc.

Provide FCF Margin
for Theralase Technologies Inc.

Show all solvency ratios
for Theralase Technologies Inc.

Provide D/E Ratio
for Theralase Technologies Inc.

Provide D/A Ratio
for Theralase Technologies Inc.

Provide Interest Coverage Ratio
for Theralase Technologies Inc.

Provide Altman Z-Score Ratio
for Theralase Technologies Inc.

Provide Quick Ratio
for Theralase Technologies Inc.

Provide Current Ratio
for Theralase Technologies Inc.

Provide Cash Ratio
for Theralase Technologies Inc.

What is the historical Revenue growth
over the last 5 years for Theralase Technologies Inc?

What is the historical Net Income growth
over the last 5 years for Theralase Technologies Inc?

What is the current Free Cash Flow
of Theralase Technologies Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Theralase Technologies Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Theralase Technologies Inc

Current Assets 1.8m
Cash & Short-Term Investments 428.4k
Receivables 569.5k
Other Current Assets 798.5k
Non-Current Assets 1.6m
PP&E 727.1k
Other Non-Current Assets 861.4k
Current Liabilities 1.5m
Accounts Payable 1.1m
Accrued Liabilities 244.8k
Other Current Liabilities 96.3k
Non-Current Liabilities 244.9k
Long-Term Debt 244.9k
Efficiency

Earnings Waterfall
Theralase Technologies Inc

Revenue
920.6k CAD
Cost of Revenue
-469.6k CAD
Gross Profit
451.1k CAD
Operating Expenses
-4.9m CAD
Operating Income
-4.4m CAD
Other Expenses
24.3k CAD
Net Income
-4.4m CAD

Free Cash Flow Analysis
Theralase Technologies Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TLT Profitability Score
Profitability Due Diligence

Theralase Technologies Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
ROIC is Increasing
Negative 1-Year Revenue Growth
25/100
Profitability
Score

Theralase Technologies Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

TLT Solvency Score
Solvency Due Diligence

Theralase Technologies Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
51/100
Solvency
Score

Theralase Technologies Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TLT Price Targets Summary
Theralase Technologies Inc

Wall Street analysts forecast TLT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TLT is 0.82 CAD with a low forecast of 0.81 CAD and a high forecast of 0.84 CAD.

Lowest
Price Target
0.81 CAD
169% Upside
Average
Price Target
0.82 CAD
172% Upside
Highest
Price Target
0.84 CAD
180% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TLT?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for TLT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Theralase Technologies Inc Logo
Theralase Technologies Inc

Country

Canada

Industry

Health Care

Market Cap

71.8m CAD

Dividend Yield

0%

Description

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.

Contact

ONTARIO
East York
41 Hollinger Rd
+14166995273.0
theralase.com

IPO

2004-11-02

Employees

-

Officers

President, CEO & Director
Mr. Roger John Dumoulin-White B.Sc., P.Eng.
CFO & Director
Ms. Kristina Hachey CPA
Chief Scientific Officer & Director
Dr. Arkady Mandel DSc., M.D., Ph.D.
President of World Trade Division
Mr. David M. Groves B.A
Equine Medical Consultant
Dr. Terry Ruch DVM

See Also

Discover More
What is the Intrinsic Value of one TLT stock?

The intrinsic value of one TLT stock under the Base Case scenario is 0.96 CAD.

Is TLT stock undervalued or overvalued?

Compared to the current market price of 0.3 CAD, Theralase Technologies Inc is Undervalued by 69%.

Back to Top